Pharmacoeconomic Analysis of Micafungin (Mycamin®) Use in the Treatment of Patients with Invasive Candidiasis | CMAC

Pharmacoeconomic Analysis of Micafungin (Mycamin®) Use in the Treatment of Patients with Invasive Candidiasis

Clinical Microbiology and Antimicrobial Chemotherapy. 2011; 13(3):267-278

Type
Journal article

Abstract

It was the first-in-Russia clinical and economic expertise of the micafungin (Mycamin) use in the treatment of adult patients with invasive candidiasis in intensive care units (ICUs). Using simulation methods, a total cost considering treatment efficacy in each group. In addition, literature review of data obtained from pharmacoeconomic studies of micafungin was performed with calculation of the both scenario (principal and alternative). In order to estimate uncertainty of the results, deterministic 1-sided sensitivity analysis was performed. In order to assess effects of parameters uncertainties on study results, Monte Carlo method was also used. This study showed that the use of micafungin for the treatment of adult patients with invasive candidiasis in ICUs is an effective and safe strategy.

Views
0 Abstract
0 PDF
0 Crossref citations
Shared